Skip to main content

Advertisement

Table 3 Drug associated adverse events (≥20 %)

From: Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan

Adverse events CTCAE ver.3 Any grade ≥ Grade 3
IFN-α alone, % Combined*, % IFN-α alone, % Combined*, %
Hand foot skin reaction 0.0 64.3 0.0 21.4
Rash 2.4 52.4 0.0 21.4
Malaise 7.1 57.1 0.0 14.3
Diarrhea 0.0 47.6 0.0 0.0
Thrombocytopenia 2.4 45.2 0.0 7.1
Anorexia 0.0 45.2 0.0 11.9
Leukocytopenia 9.5 47.6 0.0 11.9
Lipase elevation 7.1 31.0 2.4 7.1
Alopecia 0.0 35.7 0.0 0.0
Hypertension 0.0 26.2 0.0 14.3
Amylase elevation 7.1 28.6 2.4 9.5
Fatigue 0.0 26.2 0.0 4.8
Pyrexia 54.8 21.4 0.0 0.0
  1. *Combined therapy of IFN-α + sorafenib